Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
To control the global health threat of HIV by 2030, according to UNAIDS, these goals must be reached by 2020: To diagnose 90 percent of all […]
In sub-Saharan Africa where the odds of dying within a year of starting treatment for HIV can still hover close to one-in-10, diagnosing and treating TB […]
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
With more than 112,000 cases of measles reported by 170 countries so far this year, the world is seeing rising rates of a vaccine-preventable illness over […]